Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BTO vs HQL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BTO Wins Head-to-Head Institutional Verdict (1–0 across 6 Pillars · 3–1 Matrix Metrics)

BTO Overall Winner 6-Pillar Tally: BTO 1 – 0 HQL (5 Tie) Matrix Metrics: BTO 3 – 1 HQL

As of Nov 16, 2026, John Hancock Financial Opportunities Fund (BTO) is the stronger overall head-to-head candidate over abrdn Life Sciences Investors (HQL) in the Tradestie Institutional Equity Comparison Engine, winning 3–1 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Growth & Scale). BTO carries a Unified Composite Score of 43.7/100 (HOLD) at $37.34 (N/M Forward P/E, N/A operating margin), whereas HQL carries 46.0/100 (HOLD) at $17.81 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While HQL currently prints a higher short-term Unified Composite Score (46.0/100 HOLD vs. BTO 43.7/100 HOLD), BTO captures the overall institutional head-to-head verdict (3–1 matrix metrics and 1–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Technical & Structure Timing Caution: BTO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.3); meanwhile HQL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BTO vs HQL
BTO NYSE Head-to-Head Winner
John Hancock Financial Opportunities Fund
Institutional Equity
$37.34
-0.59% 1D
Market Cap $704.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.51β · 18% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 48.0 Fund 49.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -2.8%) with fading momentum, RSI 49
RSI-14: 49.3 · SMA20: $37.49 · SMA50: $37.16
HQL NYSE
abrdn Life Sciences Investors
Institutional Equity
$17.81
-2.57% 1D
Market Cap $455.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.91β · 39% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.5 · SMA20: $18.16 · SMA50: $18.45

6-Pillar Scorecard Institutional Category Breakdown (BTO 1 – 0 HQL)

Columns: Metric · BTO · HQL
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale BTO
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap $704.9M $455.0M
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BTO (3) vs HQL (1)
Institutional Metric BTO HQL Criterion Row Edge
Market Capitalization
Scale
$704.9M $455.0M Larger Scale BTO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
53% ($32–$42) 31% ($16–$23) Stronger Trend BTO
Beta / 30D Volatility
Risk Regime
0.51β · 18% Vol 0.91β · 39% Vol Lower Realized Risk BTO
Unified Institutional Score
Composite Signal
43.7 / 100 (HOLD) 46.0 / 100 (HOLD) Higher Composite HQL
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HQL +2.16 pp
BTO: +3.98% · HQL: +6.14%
3M Horizon BTO +9.05 pp
BTO: -8.95% · HQL: -18.0%
6M Horizon BTO +2.82 pp
BTO: +3.61% · HQL: +0.79%
1Y Horizon BTO +6.51 pp
BTO: +12.71% · HQL: +6.2%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BTO vs HQL. Trailing 12-month operating profitability (BTO N/A vs HQL N/A) and valuation multiples (BTO N/M vs HQL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BTO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
HQL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BTO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BTO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HQL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HQL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BTO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $704.9M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
HQL Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $455.0M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BTO vs HQL Key Questions & Quantitative Answers

As of Nov 16, 2026, John Hancock Financial Opportunities Fund (BTO) is the stronger overall head-to-head candidate over abrdn Life Sciences Investors (HQL) in the Tradestie Institutional Equity Comparison Engine, winning 3–1 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Growth & Scale). BTO carries a Unified Composite Score of 43.7/100 (HOLD) at $37.34 (N/M Forward P/E, N/A operating margin), whereas HQL carries 46.0/100 (HOLD) at $17.81 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While HQL currently prints a higher short-term Unified Composite Score (46.0/100 HOLD vs. BTO 43.7/100 HOLD), BTO captures the overall institutional head-to-head verdict (3–1 matrix metrics and 1–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: BTO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.3); meanwhile HQL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BTO leads the Growth & Scale pillar: BTO posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with HQL at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BTO generates N/A in USD-normalized revenue versus N/A for HQL. In operating R&D and SG&A reinvestment, BTO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for HQL.

BTO and HQL trade at balanced relative valuation multiples. BTO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas HQL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BTO (N/A ROE) versus HQL (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, BTO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.51β · 18% Vol realized risk). By comparison, HQL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.91β · 39% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.